Current therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and expected to drive market ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
LONDON (Reuters) - In a change of tack, Britain's healthcare cost watchdog NICE has recommended the use of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia by the state health service ...
UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement Lists Next Year UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some ...
AnaptysBio (ANAB) just shared fresh Phase 2b results for rosnilimab in rheumatoid arthritis, showing that the drug’s benefits lasted well beyond initial treatment and deepened across 28 weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback